RCM Technologies (RCMT) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 rose 3.2% year-over-year to $69.2 million, with gross profit up 6.6% to $20.0 million and net income of $3.8 million.

• Growth was led by Engineering and Specialty Health Care, with project activity ramping up and strong contributions expected from all divisions in the second half of the year.

• Life Sciences, Data and Solutions saw structural profitability improvements and continued strong client demand, despite some project timing impacts.

• The company expanded its healthcare footprint, adding new school districts and streamlining recruiting and credentialing processes.

• The company remains focused on expanding higher-margin services and investing in sales, recruiting, and infrastructure.

Financial highlights

• Q2 2024 revenue was $69.2M (+3.2% YoY); gross profit grew 6.6% to $20.0M; adjusted EBITDA increased 10.8% to $7.2M.

• Adjusted diluted EPS for Q2 2024 rose by 12.0% to $0.56; GAAP net income was $3.8M ($0.47/share).

• School revenue for Q2 2024 grew by 23.0% (excluding COVID impact), reaching $30.8M.

• Cash provided by operating activities for H1 2024 was $12.2M, down from $16.5M in the prior-year period.

• H1 2024 revenue was $141.1M (+5.2% YoY), with gross profit up 6.8% to $40.4M.

Outlook and guidance

• Expectation of continued strong engineering contributions and increased strength in other divisions in the second half of 2024.

• Optimism for low double-digit consolidated adjusted EBITDA growth for the second half of 2024 compared to 2023.

• Management expects continued growth in school client revenue within Specialty Health Care, supported by recent investments in sales and recruiting.

• The company anticipates maintaining compliance with financial covenants and sufficient liquidity for at least the next 12 months.

• Life Sciences expected to see a healthy uptick in the back half of Q3 and into Q4 as new projects ramp up.